Home
ArsenalBio

ArsenalBio Market Share Analysis for August 2026

Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.

Health > Biotechnology and Pharmaceuticals

Domainarsenalbio.com

Year Founded2018

Employees201 - 500

Annual Revenue$5M - $10M

ArsenalBio

ArsenalBio (including company regionals)

arsenalbio.com

See more website traffic and engagement information

ArsenalBio Revenue up to August 2026 is 5M - 10M

revenue generated by ArsenalBio top domains

ArsenalBio top domains revenue over 3 years

Revenue for ArsenalBio top domains

arsenalbio.com5M - 10M

See more with Sales Intelligence

Total visits to ArsenalBio's top domains

Understand ArsenalBio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

arsenalbio.com3.5K

See more with Sales Intelligence

Avg. visit duration in ArsenalBio's top domains

Analyze ArsenalBio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

arsenalbio.com00:00:35

See more with Sales Intelligence

Avg. pageviews on ArsenalBio's top domains

See how ArsenalBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

arsenalbio.com1.90

See more with Sales Intelligence

ArsenalBio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by ArsenalBio

These are the website technologies, by industry, used by ArsenalBio top domains

Content Management System (3)

WordPress

Mobile (2)

Meta Viewport

Business Solutions (1)

DocuSign

Conversion & Analytics (1)

Google Analytics

More Technologies

4

See all

News & Signals from ArsenalBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsArsenal Biosciences, Inc. decreased headcount by 99 on Aug 31st '26.ArsenalBio has cut 99 jobs, while TScan Therapeutics plans to reduce its workforce by around 75%, as both refocus on programmes designed to engineer patients' cells directly inside the body.

NewsArsenal Biosciences, Inc. attends event 43rd Annual J.P. Morgan Healthcare Conference.South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

NewsArsenal Biosciences, Inc. hired Nate Hardy as Chief Financial Officer on Oct 7th '24.Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.